 |
|
|
| |
Cabotegravir + Rilpivirine as
Long-Acting Maintenance Therapy: LATTE-2 Week 48 Results
|
| |
| |
Reported by jules Levin
Durban 2016 July 18-22
David A. Margolis,1 Daniel Podzamczer,2 Hans-Jurgen Stellbrink,3 Thomas Lutz,4
Jonathan B. Angel,5 Gary Richmond,6 Bonaventura Clotet,7 Felix Gutierrez,8 Louis Sloan,9 Sandy K. Griffith,1 Marty St Clair,1 David Dorey,10 Susan Ford,11 Joseph Mrus,12
Herta Crauwels,12 Kimberly Y. Smith,1 Peter E. Williams,12 William R. Spreen1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2Ciudad Sanitaria y Universitaria de Bellvitge, Barcelona, Spain;
3ICH Study Center, Hamburg, Germany; 4Infektio Research, Frankfurt, Germany; 5The Ottawa Hospital, Ottawa, Canada; 6Fort Lauderdale, FL, USA; 7Hospital Germans Trias i Pujol, Badalona, Spain; 8Hospital General de Elche & Universidad Miguel Hernández, Alicante, Spain; 9North Texas Infectious Disease Consultants, Dallas, TX, USA; 10GlaxoSmithKline, Mississauga, Ontario, Canada; 11PAREXEL International, Research Triangle Park, NC, USA; 12Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
